Akston Biosciences Corporation (AXTN)

Akston Biosciences Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2024	Dec 31, 2023
Net Income	1.39	3.81	-9.55
Depreciation & Amortization	1.73	1.82	1.6
Share-Based Compensation	-	0.76	0.5
Other Operating Activities	-18.21	-19.94	3.04
Operating Cash Flow	-15.08	-13.54	-4.4
Capital Expenditures	-0.94	-0.12	-0.75
Change in Investments	-	15	-
Investing Cash Flow	14.06	14.89	-0.75
Share Issuance / Repurchase	-	-	0.02
Debt Issued / Paid	-	-0.26	3.41
Financing Cash Flow	-0.55	-0.26	3.42
Net Cash Flow	-1.58	1.09	-1.72
Free Cash Flow	-16.03	-13.66	-5.15
Free Cash Flow Margin	-229.98%	-82.85%	-100.62%

Source: IPO financials are sourced from S-1 and S-1/A filings submitted to the Securities and Exchange Commission (SEC).